<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00197808</url>
  </required_header>
  <id_info>
    <org_study_id>sched1</org_study_id>
    <nct_id>NCT00197808</nct_id>
  </id_info>
  <brief_title>Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines</brief_title>
  <acronym>sched1</acronym>
  <official_title>Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Public Health England</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Public Health England</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the immune responses of UK infants after one or two&#xD;
      doses of pneumococcal conjugate vaccine or one or two doses of three different types of&#xD;
      meningococcal conjugate vaccine given at either two and three or two and four months of age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>3 months after last sample</time_frame>
    <description>SBA men C responses</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Pneumococcal Infections</condition>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>Vaccine schedule 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Menjugate vaccine at 2 and 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine schedule 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Menjugate vaccine at 2 and 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccine schedule3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neissvacc at 2 and 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccine schedule 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neissvacc at 2 and 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine schedule 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meningitec at 2 and 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine schedule 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meningitec at 2 and 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>menjugate</intervention_name>
    <description>men C conjugate vaccine</description>
    <arm_group_label>Vaccine schedule 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Men C conjugate vaccine</intervention_name>
    <description>men C conjugate vaccine</description>
    <arm_group_label>Vaccine schedule 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Men C conjugate</intervention_name>
    <description>men C conjugate vaccine</description>
    <arm_group_label>vaccine schedule3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Men C Conjugate</intervention_name>
    <description>men C conjugate vaccine</description>
    <arm_group_label>vaccine schedule 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Men C conjugate</intervention_name>
    <description>men C conjugate vaccine</description>
    <arm_group_label>Vaccine schedule 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Men C conjugate</intervention_name>
    <description>men C conjugate vaccine</description>
    <arm_group_label>Vaccine schedule 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained from parent or legal guardian of infant&#xD;
&#xD;
          -  Age 7-11 weeks at first dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindications to vaccination as specified in the UK Handbook &quot;Immunisation&#xD;
             Against Infectious Disease&quot; (Ed 1996)&#xD;
&#xD;
          -  &lt; 7 weeks or &gt; 11 weeks at first dose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Weeks</minimum_age>
    <maximum_age>11 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Coates, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Public Health England</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hertfordshire Primary Care Trusts</name>
      <address>
        <city>Welwyn Garden City</city>
        <state>Hertfordshire</state>
        <zip>AL8 6JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Primary Care Trusts</name>
      <address>
        <city>Gloucester</city>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/16567982</url>
    <description>Published study results</description>
  </link>
  <results_reference>
    <citation>Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, Tasevska J, Crowley-Luke A, Andrews N, Morris R, Borrow R, Cartwright K, Miller E. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 2006 Apr;25(4):312-9.</citation>
    <PMID>16567982</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

